The three leading voices for the lupus community in the United States – the Lupus and Allied Diseases Association, the Lupus Foundation of America and the Lupus Research Alliance – have joined together to host the Lupus Patient-Focused Drug Development (PFDD) Meeting. This groundbreaking initiative culminated in a meeting driven by persons with lupus and their advocates to provide the Food and Drug Administration (FDA) with perspective from our community on a number of important issues.
The meeting followed the successful model developed by the FDA for similar sessions and provide persons with lupus with the unique opportunity to share their story – including the challenges they face on a daily basis in living with lupus and their hopes for future treatments – with senior FDA officials to better inform how the agency evaluates and considers potential therapies for lupus.
Held on September 25 in the Washington, DC suburb of Hyattsville, Maryland, the Lupus PFDD Meeting featured upwards of 100 persons with lupus as well as their representatives, including two diverse panels of people affected by lupus who will share their stories and drive the conversation. Following the meeting, the organizers will summarize the session as well as the input received through the pre-meeting survey and share this report with the FDA, pharmaceutical developers, researchers and others working to produce treatments for lupus.
The Lupus and Allied Diseases Association, the Lupus Foundation of America and the Lupus Research Alliance are tremendously excited about this project and its impact on our goals of improving patient quality of life through the discovery and delivery of better treatments and, ultimately, of curing this disease. We thank those who have joined this effort to help us move toward a world free of lupus.